Abstract
Early diagnosis of Parkinson's disease (PD) is important because it affects the choice of therapy and is subject to a relatively high degree of error. In addition, early detection of PD can potentially enable the start of neuroprotective therapy before extensive loss of dopaminergic neurons of the substantia nigra occurs. However, until now, studies for early detection of PD using volatile biomarkers sampled only treated and medicated patients. Therefore, there is a great need to evaluate untreated patients for establishing a real world screening and diagnostic technology. Here we describe for the first time a clinical trial to distinguish between de novo PD and control subjects using an electronic system for detection of volatile molecules in exhaled breath (sensor array). We further determine for the first time the association to other common tests for PD diagnostics as smell, ultrasound, and nonmotor symptoms. The test group consisted of 29 PD patients after initial diagnosis by an experienced neurologist, compared with 19 control subjects of similar age. The sensitivity, specificity, and accuracy values of the sensor array to detect PD from controls were 79%, 84%, and 81% respectively, in comparison with midbrain ultrasonography (93%, 90%, 92%) and smell detection (62%, 89%, 73%). The results confirm previous data showing the potential of sensor arrays to detect PD.
| Original language | English |
|---|---|
| Pages (from-to) | 2548-2553 |
| Number of pages | 6 |
| Journal | ACS Chemical Neuroscience |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| State | Published - 21 Nov 2018 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:Copyright © 2018 American Chemical Society.
Funding
*J.P.M.F. E-mail: [email protected]. *H.H. E-mail: [email protected]. ORCID Hossam Haick: 0000-0002-2370-4073 Author Contributions ⊥J.P.M.F. and R.J. made equal contributions. J.P.M.F. contributed project initiation, design, and direction and manuscript writing. M.S. contributed preparation of the clinical protocol for the study, submission of ethical application for center 1, and patient recruitment and clinical assessment of disease state center 1, was the responsible clinician for collection of breath samples and additional tests at center 1, and performed all ultrasound determinations. R.J. provided sample collection, sample analysis, data analysis, figure construction, and manuscript writing. S.B. contributed preparation of the clinical protocol for the study, submission of ethical application for center 2, and patient recruitment and clinical assessment of disease state at center 2 and was the responsible clinician for collection of breath samples and additional tests at center 2. M.K.N. contributed data analysis. E.D. contributed to clinical work with patients at center 2, data collection and organization at center 2, and statistical determinations on patient data. Y.A. contributed clinical work with patients at center 1 and data collection and organization at center 1. M.A.H. contributed to data analysis. Y.Y.B. contributed to data interpretation, figure construction, and manuscript revision. H.H. contributed joint conception, coordination, and management of the project and manuscript revision. Funding This research was funded from the Kamin Research Fund of the Israeli Ministry of Commerce and Britain Israel Research and Academic Exchange Partnership (BIRAX; 62BX14RBHH). Notes The authors declare no competing financial interest. #Deceased.
| Funders | Funder number |
|---|---|
| BIRAX | 62BX14RBHH |
| Israeli Ministry of Commerce and Britain Israel Research and Academic Exchange Partnership |
Keywords
- Parkinson
- UPSIT
- ultrasonography
- volatile organic compound
- volatolomics